Literature DB >> 2154250

Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity.

G Capranico1, F Zunino, K W Kohn, Y Pommier.   

Abstract

Topoisomerase II mediated double-strand breaks produced by anthracycline analogues were studied in SV40 DNA. The compounds included doxorubicin, daunorubicin, two doxorubicin stereoisomers (4'-epimer and beta-anomer), and five chromophore-modified derivatives, with a wide range of cytotoxic activity and DNA binding affinity. Cleavage of 32P-end-labeled DNA fragments was visualized by autoradiography of agarose and polyacrylamide gels. Structure-activity relationships indicated that alterations in the chromophore structure greatly affected drug action on topoisomerase II. In particular, removal of substituents on position 4 of the D ring resulted in more active inducers of cleavage with lower DNA binding affinity. The stereochemistry between the sugar and the chromophore was also essential for activity. All the active anthracyclines induced a single region of prominent cleavage in the entire SV40 DNA, which resulted from a cluster of sites between nucleotides 4237 and 4294. DNA cleavage intensity patterns exhibited differences among analogues and were also dependent upon drug concentration. Intensity at a given site depended on both stimulatory and suppressive effects depending upon drug concentration and DNA sequence. A good correlation was found between cytotoxicity and intensity of topoisomerase II mediated DNA breakage.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154250     DOI: 10.1021/bi00454a033

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  32 in total

1.  The recognition of DNA cleavage sites by porcine spleen topoisomerase II.

Authors:  H W Huang; J K Juang; H J Liu
Journal:  Nucleic Acids Res       Date:  1992-02-11       Impact factor: 16.971

2.  Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

Authors:  Y Pommier; G Capranico; A Orr; K W Kohn
Journal:  Nucleic Acids Res       Date:  1991-11-11       Impact factor: 16.971

3.  Nucleosome positioning as a critical determinant for the DNA cleavage sites of mammalian DNA topoisomerase II in reconstituted simian virus 40 chromatin.

Authors:  G Capranico; C Jaxel; M Roberge; K W Kohn; Y Pommier
Journal:  Nucleic Acids Res       Date:  1990-08-11       Impact factor: 16.971

4.  Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.

Authors:  Hideki Asakawa; Hirotaka Koizumi; Ayaka Koike; Makiko Takahashi; Wenwen Wu; Hirotaka Iwase; Mamoru Fukuda; Tomohiko Ohta
Journal:  Breast Cancer Res       Date:  2010-03-05       Impact factor: 6.466

5.  Engineered biosynthesis of aklanonic acid analogues.

Authors:  Taek Soon Lee; Chaitan Khosla; Yi Tang
Journal:  J Am Chem Soc       Date:  2005-09-07       Impact factor: 15.419

Review 6.  DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.

Authors:  Y Pommier
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage.

Authors:  M Bigioni; F Zunino; G Capranico
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

8.  Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding.

Authors:  F Gieseler; H Biersack; T Brieden; J Manderscheid; V Nüssler
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

Review 9.  Clinical pharmacokinetics of idarubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

10.  Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin.

Authors:  N Fujii; Y Yamashita; Y Arima; M Nagashima; H Nakano
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.